Oscar Health (OSCR) Q2 2025: Double-Digit Rate Filings Signal Sharp Morbidity Reset for 2026
Oscar Health faces a market-wide morbidity surge, triggering repricing and double-digit 2026 rate filings across nearly all states. The company is pulling multiple levers—expense cuts, AI-driven efficiencies, and new ICRA marketplace assets—to offset near-term operating losses and target a return to profitability next year. With regulators and peers signaling similar rate hikes, Oscar’s strategic posture now centers on risk discipline and long-term individual market positioning.
Summary
- Market Morbidity Spike: Oscar responds to elevated claims by repricing for 2026 and tightening risk controls.
- Cost Discipline Intensifies: Workforce reductions and AI-driven SG&A cuts target $60 million in savings next year.
- ICRA and Marketplace Diversification: New assets and partnerships aim to broaden Oscar’s reach beyond core ACA plans.
Performance Analysis
Oscar’s Q2 performance was dominated by a sharp shift in market morbidity, with the medical loss ratio (MLR, claims paid as a percent of premium) rising 12 points to 91.1% due to higher-than-expected risk adjustment payables. This spike reflects a broader ACA market trend, as newly enrolled high-utilization members (often from Medicaid redeterminations) outpaced healthy, low-utilization exits. Revenue rose 29% year over year, driven by 2 million members—up 28%—but the operating loss widened to $230 million, with adjusted EBITDA loss at $199 million.
Utilization trends moderated sequentially through the quarter, with inpatient use still elevated but offset by pharmacy favorability. Outpatient and professional services tracked expectations. Administrative efficiency improved, as the SG&A ratio dropped 90 basis points to 18.7%, reflecting fixed cost leverage and early AI benefits. Oscar’s capital position remains robust, with $5.4 billion in cash and investments and $579 million in excess subsidiary capital, providing a buffer for projected full-year losses.
- Risk Adjustment Headwind: Q2 included a $316 million incremental risk adjustment payable, compressing margins and driving the MLR spike.
- Membership Retention: Strong retention and SEP (special enrollment period) additions sustained above-market growth, but new members’ risk profiles tracked historical patterns.
- Expense Management: SG&A savings were realized through fixed cost reductions, vendor cuts, and AI-driven process improvements.
Oscar’s financials reflect a market in reset mode, with top-line growth offset by morbidity-driven cost pressure and a pivot toward aggressive repricing for 2026.
Executive Commentary
"We resubmitted 2026 rate filings in states covering nearly all current membership to reflect morbidity increases. Our engagement with state regulators continues to be productive. We expect the market will have double-digit rate increases next year. We believe these overall rate increases will address the current morbidity pressure and the effects of program integrity efforts for 2026."
Mark Bertolini, Chief Executive Officer
"There is a market-wide shift occurring in the ACA marketplace shifting towards higher average market morbidity. While we are now projecting a loss for 2025, we are taking corrective actions to ensure we are well positioned to return to profitability next year."
Scott Blackley, Chief Financial Officer
Strategic Positioning
1. Aggressive Repricing and Regulatory Engagement
Oscar’s core response to the morbidity shock is repricing: The company resubmitted 2026 rate filings in nearly all states to reflect the new risk pool, with management expecting “double-digit” premium increases. Regulatory dialogue has been collaborative, with state agencies prioritizing sustainable pricing to avoid market destabilization. Oscar’s rates are positioned to match or exceed larger peers, aiming to avoid adverse selection and maintain risk pool stability.
2. Cost Structure Overhaul and AI Leverage
Expense discipline is a central theme, with a targeted $60 million reduction in administrative costs for 2026. Half the savings will come from workforce reductions, while the balance is driven by closing open roles and vendor renegotiations. AI-driven efficiencies, including new agentic AI deployments in clinical operations, underpin both immediate SG&A improvements and long-term scalability.
3. ICRA and Marketplace Diversification
Oscar is expanding beyond its traditional ACA individual market by acquiring early-stage assets: a brokerage (IHC Specialty Benefits), a CMS-approved digital enrollment platform (INSXcloud), and a consumer education site (healthinsurance.org). These assets position Oscar to capitalize on the growing ICRA (Individual Coverage Health Reimbursement Arrangement) market, highlighted by a new partnership with Hy-Vee for a branded plan in Iowa. While near-term financial impact is limited, these moves signal a push toward a broader consumer health marketplace model.
4. Risk Management and Capital Resilience
Oscar’s strong capital position acts as a shock absorber, with $5.4 billion in cash and investments and minimal leverage. The company expects to absorb 2025 losses via existing excess capital, while maintaining parent cash above internal targets. Management emphasized readiness to access additional capital if needed, supported by an unlevered balance sheet and an expiring revolver that is in the process of being renewed.
5. Disciplined Membership and Product Strategy
Oscar is actively managing enrollment to avoid adverse risk selection, using market-specific pricing and product design to prevent absorbing disproportionate high-risk members from competitors. Retention remains strong, and new member risk profiles are consistent with historical averages, mitigating further risk pool deterioration.
Key Considerations
This quarter marks a strategic inflection point for Oscar, as management pivots to address industry-wide morbidity shifts while laying groundwork for new growth vectors.
Key Considerations:
- ACA Market Reset: Elevated morbidity and risk adjustment payables are not Oscar-specific, but reflect a broad ACA market reset, requiring synchronized repricing across carriers.
- Expense Reduction Execution: Delivering $60 million in SG&A cuts will test Oscar’s operational discipline, especially as AI-driven initiatives scale from pilot to core processes.
- ICRA and Digital Marketplace Bet: Early-stage acquisitions and the Hy-Vee partnership are strategic, but require execution to drive meaningful diversification and margin expansion.
- Regulatory and Competitive Dynamics: State regulators are aligned on market stability, but actual rate approvals and peer pricing behavior remain sources of uncertainty.
Risks
Oscar’s outlook depends on the effectiveness of repricing and the accuracy of morbidity assumptions, with potential for further risk pool deterioration if competitive dynamics or regulatory changes diverge from expectations. Uncertainty around the extension of enhanced premium tax credits and the impact of end-of-year utilization spikes could pressure results. Execution risk exists in both cost reduction plans and the scaling of new ICRA and digital marketplace ventures.
Forward Outlook
For Q3 and Q4 2025, Oscar guided to:
- Continued moderation in SEP member additions as eligibility rules tighten
- Full-year MLR in the 86% to 87% range, reflecting persistent morbidity pressure
For full-year 2025, management reaffirmed guidance:
- Total revenue of $12 billion to $12.2 billion
- Operating loss of $200 million to $300 million
- SG&A ratio of 17.1% to 17.6%
Management stressed that 2026 rate filings fully reflect higher morbidity, program integrity effects, and subsidy expirations, setting the stage for a targeted return to profitability. Key drivers will be the pace of SG&A reductions, successful rate approvals, and the stabilization of the risk pool.
Takeaways
Oscar’s Q2 results crystallize a market-wide reset, with the company repricing aggressively and slashing costs to restore profitability in 2026.
- Morbidity-Driven Margin Compression: The sharp rise in MLR and risk adjustment payables is an industry-wide phenomenon, but Oscar’s rapid repricing and risk controls aim to prevent further erosion.
- Cost Structure Transformation: SG&A savings and AI-driven efficiencies are central to bridging the gap to profitability, with execution risk around workforce and process transformation.
- ICRA and Platform Expansion: Early-stage marketplace acquisitions and the Hy-Vee partnership are strategic bets on the future of consumer-driven health insurance, though their impact will take time to materialize.
Conclusion
Oscar Health is at a pivotal juncture, responding to ACA morbidity shocks with repricing, cost discipline, and digital marketplace expansion. The company’s ability to execute on rate approvals, SG&A cuts, and new growth vectors will determine whether it can deliver on its 2026 profitability target and maintain its position as a leader in a rapidly evolving individual market.
Industry Read-Through
Oscar’s experience this quarter is a bellwether for the broader ACA individual market, where rising morbidity and risk adjustment volatility are forcing carriers to reprice aggressively and rethink risk management. The prevalence of double-digit rate filings, collaborative regulatory stances, and widespread cost-cutting signal a sector-wide reset. Insurers with advanced technology, diversified product strategies, and strong capital positions will be best positioned to weather continued volatility and capitalize on emerging opportunities like ICRA and digital health marketplaces. Investors should monitor rate approval processes, subsidy policy developments, and the competitive response from larger carriers for further sector implications.